Tag:
Diabetes
Latest Headlines
Latest Headlines
Pfizer adds healthy-eating app to Lipitor marketing arsenal
The drugmaker teamed up with EatingWell magazine to develop a mobile app, dubbed Recipes 2 Go, and a sister website, lipitorsmartliving.com. The mobile app hooks into Pfizer's Lipitor co-pay card offer with a feature that makes refills easier.
Novo confident that it can crack blockbuster oral insulin market
Novo Nordisk says it's willing to bet $2 billion that it can score a mega-blockbuster success in the field.
Lilly posts clean safety data on PhIII diabetes blockbuster hopeful
Eli Lilly CEO John Lechleiter has made it clear that dulaglutide is one of the company's top blockbuster hopefuls in its late-stage pipeline.
HGS faces skeptics as it boasts of a crowded bargaining table
Human Genome Sciences has prescribed a poison pill for GlaxoSmithKline's hostile takeover bid.
Big-name pharmas peer at Amylin's books to prep for bids
The world's biggest drugmakers have lined up to take a look at Amylin's books as the U.S.-based company prepares to entertain a first round of bids.
Docs riled by FDA's proposal to open up drug access
The FDA would free up some treatments for chronic conditions, such as asthma and diabetes, so patients could obtain them without a prescription.
UPDATED: Novo Nordisk hiring R&D, other workers in U.S. recruitment blitz
Novo Nordisk says it plans to boost its U.S. workforce almost 15% this year amid growth in the Danish drugmaker's diabetes business.
Takeda rebuffed (again) in long quest for FDA drug OK
Four months before Japan's Takeda will get hit with generic competition for the diabetes blockbuster Actos, the FDA has once again rebuffed the company's application to sell the experimental drug alogliptin.
Buzz: Amylin brings in the bankers to spur an auction
Amylin has never confirmed or denied the much repeated story that it rejected a $22 per share bid for the company by Bristol-Myers Squibb.
Victoza gets superior-to-Januvia data added to label
The change comes after a study showed Novo's drug outperformed Merck's at controlling blood sugar and helping patients lose weight.
